Business
FDA Lifts Clinical Hold on NUZ-001
Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational drug, NUZ‑001. This decision marks a pivotal regulatory milestone for Neurizon and the ALS community, clearing the way for Phase 2/3 development of NUZ-001 as part of the HEALEY ALS
About this update from Neurizon Therapeutics Limited
[{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational therapy for ALS","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Clears the way for entry into the HEALEY ALS Platform Trial expected to commence in Q4 CY2025 ","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"IND supported by robust preclinical safety data and comprehensive manufacturing and quality information from the previously signed Elanco licensing agreement","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Expedites NUZ-001 as a platform molecule with pipeline expansion potential","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Positions Neurizon for accelerated regulatory pathways and future partnering opportunities","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":511,"olType":false},{"type":"text","content":"MELBOURNE, Australia, Oct. 6, 2025 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational drug, NUZ‑001. This decision marks a pivotal regulatory milestone for Neurizon and the ALS community, clearing the way for Phase 2/3 development of NUZ-001 as part of the HEALEY ALS Platform Trial, expected to commence Q4 CY2025.","length":628,"tagName":"p"},{"type":"image","alt":"Neurizon Therapeutics Master Logo (PRNewsfoto/Neurizon Therapeutics Limited)","displaySize":"","headline":null,"caption":"Neurizon Therapeutics Master Logo (PRNewsfoto/Neurizon Therapeutics Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":113,"url":"https://media.zenfs.com/en/prnewswire.com/04d0d9d409913dfec3923dc98767d531"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RsdVU5pKYuarm1ExFCC2.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/04d0d9d409913dfec3923dc98767d531","width":400,"height":113}},"href":"https://mma.prnewswire.com/media/2530795/Neurizon_Logo.html","hrefExternal":true,"rel":...